Comparing Two Different Chemotherapy Schedules for New Acute Myeloid Leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether giving chemotherapy drugs on a 2-week schedule versus a 3-week schedule works better for newly diagnosed acute myeloid leukemia (a blood cancer). The goal is to find which schedule helps more patients go into remission (where cancer cells disappear).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been newly diagnosed with acute myeloid leukemia (AML) and not received any cancer treatment before
- You must be between 18 and 75 years old
- You must weigh between 66 and 220 pounds (30–100 kg)
- Your heart, liver, and kidneys must be working reasonably well (checked by blood tests and heart ultrasound)
- You cannot have a serious infection at the time you join
- You must be able to understand the study and agree to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different intensities of venetoclax (a targeted pill) combined with standard chemotherapy for people newly diagnosed with acute myeloid leukemia (AML). The goal is to find out which dose works better and is safer.
This trial compares a new combination of drugs (venetoclax, azacitidine, and liposomal mitoxantrone) against a standard chemotherapy regimen (idarubicin and cytarabine) for people with newly diagnosed acute myeloid leukemia (AML). It tests whether the new combination works better and is safe.
This study compares two types of chemotherapy for people with newly diagnosed acute myeloid leukemia (AML). The goal is to see which treatment better lowers signs of cancer in the blood, using a special test that looks for a chemical mark on DNA.
This trial tests if adding a second drug (venetoclax) to a standard chemotherapy (azacitidine) works better than the standard alone for adults aged 60 to 75 with newly diagnosed acute myeloid leukemia (AML).
This trial tests a combination of three chemotherapy drugs (venetoclax, azacitidine, and cytarabine) for people newly diagnosed with acute myeloid leukemia who have never received AML treatment before. The goal is to see if this combination can help patients go into remission and live longer.
This trial tests a new combination of venetoclax plus a chemotherapy regimen (called CACAG) against a standard chemotherapy regimen (3+7) for adults with newly diagnosed intermediate- or high-risk AML. The goal is to see if the new combination works better.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.